← All Eli Lilly & CO filings

Eli Lilly & CO 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
LLY
Eli Lilly & CO
10-K: Eli Lilly Soars on Blockbuster Drug Sales, Robust Pipeline
Eli Lilly reported exceptional financial growth in 2025, driven by strong demand for its cardiometabolic health products, while navigating a complex regulatory and competitive landscape.
NYSE
LLY
Eli Lilly & CO
10-K: Eli Lilly Reports Strong 2024 Results, Driven by New Products and Strategic Investments
Eli Lilly's 2024 annual report highlights significant revenue growth driven by key products like Mounjaro and Zepbound, alongside strategic investments in research and development and manufacturing capacity.
NYSE
LLY
Eli Lilly & CO
10-K: Eli Lilly Details Common Stock Structure and Anti-Takeover Measures in 10-K Filing
Eli Lilly's 10-K filing outlines the structure of its common stock, dividend rights, liquidation rights, voting rights, and various anti-takeover provisions.